Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results Academic Article uri icon

Overview

MeSH Major

  • Antigen Presentation
  • HSP90 Heat-Shock Proteins
  • Histocompatibility Antigens Class I

abstract

  • With longer follow-up, NIVO3 demonstrated sustained antitumor activity alone and in combination with ipilimumab. NIVO1+IPI3 provided the greatest antitumor activity of all regimens, with a manageable safety profile. This result not only supports additional study of NIVO1+IPI3 in mUC, but demonstrates the potential benefit of immunotherapy combinations in this disease.

publication date

  • January 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.19.00538

PubMed ID

  • 31100038

Additional Document Info

start page

  • 1608

end page

  • 1616

volume

  • 37

number

  • 19